Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apples And Oranges? Not All PI3 Kinase Inhibitors Are Created Equal

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

As development and deal-making activity in the phosphatidyinositol-3-kinase (PI3 kinase) area increases, a crucial question has emerged. Will early investments in pan-selective PI3 kinase inhibitors pay off, or will the more recent focus on isoform-selective compounds prove the better approach to this space?

You may also be interested in...



Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors

Exelixis cashes in on a hot therapeutic drug target, showing that an R&D-focused biotech can succeed in the marketplace.

Roche Acquires Genentech Oncology Partner Piramed

$175 million deal nets Roche a novel program of signal transduction inhibitors with utility in cancer and inflammatory disease.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel